<p>Crescent Park Management L.P. 在最近向美國證券交易委員會（SEC）披露的信息中表示，其在 Cellebrite DI Ltd.（NASDAQ:CLBT - 免費報告）的持股在第二季度減少了 16.6%。該基金在此期間出售了 113,179 股後，持有 570,232 股該公司的股票。Cellebrite DI 大約佔 Crescent Park Management L.P.持股的 3.5%，是其第 12 大持倉。截至最近的 SEC 文件，Crescent Park Management L.P.持有的 Cellebrite DI 的股份約佔 0.24%，價值 9,124,000 美元。</p>
<p>其他幾家對沖基金和機構投資者最近也對 CLBT 的持倉進行了調整。T. Rowe Price Investment Management Inc.在第一季度購買了 Cellebrite DI 的新頭寸，價值約為 60,939,000 美元。Invesco Ltd.在第一季度將其在 Cellebrite DI 的股份增加了 122.1%。Invesco Ltd.現在持有 3,296,079 股該公司的股票，價值 64,043,000 美元，此前在上個季度又收購了 1,811,757 股。Phoenix Financial Ltd.在第二季度將其在 Cellebrite DI 的持股增加了 153.5%。Phoenix Financial Ltd.現在持有 2,014,617 股該公司的股票，價值 32,232,000 美元，此前在上個季度又收購了 1,219,958 股。Handelsbanken Fonder AB 在第二季度將其在 Cellebrite DI 的持倉提高了 61.3%。Handelsbanken Fonder AB 現在持有 2,450,000 股該公司的股票，價值 39,200,000 美元，此前在上個季度又購買了 931,300 股。最後，加拿大皇家銀行在第一季度將其在 Cellebrite DI 的持股增加了 11,705.0%。加拿大皇家銀行現在持有 824,226 股該公司的股票，價值 16,015,000 美元，此前在上個季度又購買了 817,244 股。對沖基金和其他機構投資者持有該公司 45.88% 的股票。</p>
<p>獲取 <strong>Cellebrite DI</strong> 的提醒：</p>
<h2>Cellebrite DI 價格表現</h2>
<p>CLBT 股票在週二開盤價為 17.14 美元。Cellebrite DI Ltd.的 1 年最低價為 13.10 美元，1 年最高價為 26.30 美元。該公司的市值為 41 億美元，市盈率為-22.55，市盈增長比率為 3.16，貝塔值為 1.28。該股票的 50 日移動平均價格為 17.79 美元，200 日移動平均價格為 16.50 美元。</p>
<p>Cellebrite DI（NASDAQ:CLBT - 獲取免費報告）最近在 11 月 12 日（星期三）發佈了季度財報。該公司報告的季度每股收益（EPS）為 0.08 美元，低於分析師一致預期的 0.13 美元，差額為 0.05 美元。該公司季度收入為 1.2603 億美元，而分析師預期為 1.2298 億美元。Cellebrite DI 的淨利潤率為-34.56%，股本回報率為 23.92%。該公司的收入較去年同期增長了 17.9%。去年同期，該公司每股收益為 0.14 美元。Cellebrite DI 已設定 2025 財年的每股收益指導。2025 年第四季度的指導為每股收益。整體來看，分析師預計 Cellebrite DI Ltd.今年的每股收益為 0.3。</p>
<h2>分析師設定新目標價</h2>
<p>多位分析師對該股票發表了看法。美國銀行在 11 月 13 日（星期四）的研究報告中將 Cellebrite DI 的目標價從 24.00 美元上調至 25.00 美元，並給予該公司 “買入” 評級。摩根大通將 Cellebrite DI 的目標價從 23.00 美元上調至 24.00 美元，並在 11 月 13 日（星期四）的研究報告中給予該公司 “增持” 評級。Weiss Ratings 在 11 月 25 日（星期二）的報告中重申了對 Cellebrite DI 的 “賣出（d-）” 評級。Lake Street Capital 在 11 月 13 日（星期四）的研究報告中將 Cellebrite DI 的目標價從 22.00 美元上調至 23.00 美元，並給予該公司 “買入” 評級。最後，Needham &amp; Company LLC 在 11 月 13 日（星期四）的研究報告中將 Cellebrite DI 的目標價從 22.00 美元上調至 24.00 美元，並給予該股票 “買入” 評級。四位股票研究分析師對該股票給予了 “買入” 評級，一位分析師給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 24.00 美元。</p>
<p><strong>查看我們關於 CLBT 的最新報告</strong></p>
<h2>Cellebrite DI 公司簡介</h2>
<p>（免費報告）</p>
<p>Cellebrite DI Ltd.為歐洲、中東、非洲、美洲和亞太地區的合法調查開發解決方案。該公司的 DI 解決方案套件允許用户在調查生命週期內收集、審查、分析和管理數字數據，涉及各種案件的合法調查，包括兒童剝削、謀殺、反恐、邊境控制、性犯罪、人口販賣、企業安全、加密貨幣和知識產權盜竊。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Cellebrite DI</li>
<li>投資的股票類型有不同</li>
<li>預計 2025 年上漲超過 20%，這三隻股票正在提升回購能力</li>
<li>加拿大便士股票：它們能讓你致富嗎？</li>
<li>國會再次超越市場——這是他們購買的三隻股票</li>
<li>消費者可選股票解析</li>
<li>與三隻頂級零售 ETF 一起購物</li>
</ul>
<p><strong>想看看其他對沖基金持有的 CLBT 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Cellebrite DI Ltd.（NASDAQ:CLBT - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xCVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Cellebrite DI 嗎？</h2>
<p>在你考慮 Cellebrite DI 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Cellebrite DI 並不在名單上。</p>
<p>雖然 Cellebrite DI 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CLBT

<p>Crescent Park Management L.P. 在第二季度減少了對 Cellebrite DI Ltd. 的持股比例，降幅為 16.6%，目前持有 570,232 股。其他機構投資者也調整了他們在 CLBT 的頭寸。該股票開盤價為 17.14 美元，市值為 41 億美元。分析師的評級意見不一，普遍共識為 “適度買入”，平均目標價格為 24.00 美元</p>

<p>Crescent Park Management L.P. trimmed its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 16.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 570,232 shares of the company's stock after selling 113,179 shares during the period. Cellebrite DI makes up approximately 3.5% of Crescent Park Management L.P.'s holdings, making the stock its 12th largest position. Crescent Park Management L.P. owned approximately 0.24% of Cellebrite DI worth $9,124,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Crescent Park Management L.P. 在最近向美國證券交易委員會（SEC）披露的信息中表示，其在 Cellebrite DI Ltd.（NASDAQ:CLBT - 免費報告）的持股在第二季度減少了 16.6%。該基金在此期間出售了 113,179 股後，持有 570,232 股該公司的股票。Cellebrite DI 大約佔 Crescent Park Management L.P.持股的 3.5%，是其第 12 大持倉。截至最近的 SEC 文件，Crescent Park Management L.P.持有的 Cellebrite DI 的股份約佔 0.24%，價值 9,124,000 美元。</p>
</div><p>Several other hedge funds and other institutional investors also recently made changes to their positions in CLBT. T. Rowe Price Investment Management Inc. bought a new position in Cellebrite DI during the 1st quarter valued at approximately $60,939,000. Invesco Ltd. grew its stake in shares of Cellebrite DI by 122.1% in the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock worth $64,043,000 after acquiring an additional 1,811,757 shares during the last quarter. Phoenix Financial Ltd. increased its holdings in shares of Cellebrite DI by 153.5% during the second quarter. Phoenix Financial Ltd. now owns 2,014,617 shares of the company's stock valued at $32,232,000 after acquiring an additional 1,219,958 shares in the last quarter. Handelsbanken Fonder AB raised its position in shares of Cellebrite DI by 61.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 2,450,000 shares of the company's stock worth $39,200,000 after purchasing an additional 931,300 shares during the last quarter. Finally, Royal Bank of Canada boosted its stake in Cellebrite DI by 11,705.0% in the 1st quarter. Royal Bank of Canada now owns 824,226 shares of the company's stock worth $16,015,000 after purchasing an additional 817,244 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者最近也對 CLBT 的持倉進行了調整。T. Rowe Price Investment Management Inc.在第一季度購買了 Cellebrite DI 的新頭寸，價值約為 60,939,000 美元。Invesco Ltd.在第一季度將其在 Cellebrite DI 的股份增加了 122.1%。Invesco Ltd.現在持有 3,296,079 股該公司的股票，價值 64,043,000 美元，此前在上個季度又收購了 1,811,757 股。Phoenix Financial Ltd.在第二季度將其在 Cellebrite DI 的持股增加了 153.5%。Phoenix Financial Ltd.現在持有 2,014,617 股該公司的股票，價值 32,232,000 美元，此前在上個季度又收購了 1,219,958 股。Handelsbanken Fonder AB 在第二季度將其在 Cellebrite DI 的持倉提高了 61.3%。Handelsbanken Fonder AB 現在持有 2,450,000 股該公司的股票，價值 39,200,000 美元，此前在上個季度又購買了 931,300 股。最後，加拿大皇家銀行在第一季度將其在 Cellebrite DI 的持股增加了 11,705.0%。加拿大皇家銀行現在持有 824,226 股該公司的股票，價值 16,015,000 美元，此前在上個季度又購買了 817,244 股。對沖基金和其他機構投資者持有該公司 45.88% 的股票。</p>
</div><p>Get <strong>Cellebrite DI</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Cellebrite DI</strong> 的提醒：</p>
</div><h2>Cellebrite DI Price Performance</h2>
<div class="lb-trans"><h2>Cellebrite DI 價格表現</h2>
</div><p>CLBT stock opened at $17.14 on Tuesday. Cellebrite DI Ltd. has a 1 year low of $13.10 and a 1 year high of $26.30. The company has a market cap of $4.10 billion, a P/E ratio of -22.55, a price-to-earnings-growth ratio of 3.16 and a beta of 1.28. The stock's fifty day moving average price is $17.79 and its 200-day moving average price is $16.50.</p>
<div class="lb-trans"><p>CLBT 股票在週二開盤價為 17.14 美元。Cellebrite DI Ltd.的 1 年最低價為 13.10 美元，1 年最高價為 26.30 美元。該公司的市值為 41 億美元，市盈率為-22.55，市盈增長比率為 3.16，貝塔值為 1.28。該股票的 50 日移動平均價格為 17.79 美元，200 日移動平均價格為 16.50 美元。</p>
</div><p>Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.13 by ($0.05). The firm had revenue of $126.03 million for the quarter, compared to analysts' expectations of $122.98 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The firm's revenue was up 17.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.14 EPS. Cellebrite DI has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.</p>
<div class="lb-trans"><p>Cellebrite DI（NASDAQ:CLBT - 獲取免費報告）最近在 11 月 12 日（星期三）發佈了季度財報。該公司報告的季度每股收益（EPS）為 0.08 美元，低於分析師一致預期的 0.13 美元，差額為 0.05 美元。該公司季度收入為 1.2603 億美元，而分析師預期為 1.2298 億美元。Cellebrite DI 的淨利潤率為-34.56%，股本回報率為 23.92%。該公司的收入較去年同期增長了 17.9%。去年同期，該公司每股收益為 0.14 美元。Cellebrite DI 已設定 2025 財年的每股收益指導。2025 年第四季度的指導為每股收益。整體來看，分析師預計 Cellebrite DI Ltd.今年的每股收益為 0.3。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of analysts have weighed in on the stock. Bank of America raised their price objective on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, November 13th. JPMorgan Chase &amp; Co. raised their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday, November 13th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Cellebrite DI in a report on Tuesday, November 25th. Lake Street Capital increased their target price on Cellebrite DI from $22.00 to $23.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, November 13th. Finally, Needham &amp; Company LLC boosted their price target on Cellebrite DI from $22.00 to $24.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $24.00.</p>
<div class="lb-trans"><p>多位分析師對該股票發表了看法。美國銀行在 11 月 13 日（星期四）的研究報告中將 Cellebrite DI 的目標價從 24.00 美元上調至 25.00 美元，並給予該公司 “買入” 評級。摩根大通將 Cellebrite DI 的目標價從 23.00 美元上調至 24.00 美元，並在 11 月 13 日（星期四）的研究報告中給予該公司 “增持” 評級。Weiss Ratings 在 11 月 25 日（星期二）的報告中重申了對 Cellebrite DI 的 “賣出（d-）” 評級。Lake Street Capital 在 11 月 13 日（星期四）的研究報告中將 Cellebrite DI 的目標價從 22.00 美元上調至 23.00 美元，並給予該公司 “買入” 評級。最後，Needham &amp; Company LLC 在 11 月 13 日（星期四）的研究報告中將 Cellebrite DI 的目標價從 22.00 美元上調至 24.00 美元，並給予該股票 “買入” 評級。四位股票研究分析師對該股票給予了 “買入” 評級，一位分析師給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 24.00 美元。</p>
</div><p><strong>Check Out Our Latest Report on CLBT</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CLBT 的最新報告</strong></p>
</div><h2>Cellebrite DI Company Profile</h2>
<div class="lb-trans"><h2>Cellebrite DI 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.</p>
<div class="lb-trans"><p>Cellebrite DI Ltd.為歐洲、中東、非洲、美洲和亞太地區的合法調查開發解決方案。該公司的 DI 解決方案套件允許用户在調查生命週期內收集、審查、分析和管理數字數據，涉及各種案件的合法調查，包括兒童剝削、謀殺、反恐、邊境控制、性犯罪、人口販賣、企業安全、加密貨幣和知識產權盜竊。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Cellebrite DI</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity</li>
<li>Canadian Penny Stocks: Can They Make You Rich?</li>
<li>Congress Beat the Market Again—Here Are the 3 Stocks They Bought</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>Go on a Shopping Spree With 3 Top Retail ETFs</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Cellebrite DI</li>
<li>投資的股票類型有不同</li>
<li>預計 2025 年上漲超過 20%，這三隻股票正在提升回購能力</li>
<li>加拿大便士股票：它們能讓你致富嗎？</li>
<li>國會再次超越市場——這是他們購買的三隻股票</li>
<li>消費者可選股票解析</li>
<li>與三隻頂級零售 ETF 一起購物</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CLBT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 CLBT 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Cellebrite DI Ltd.（NASDAQ:CLBT - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CLBT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cellebrite DI Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Cellebrite DI 嗎？</h2>
</div><p>Before you consider Cellebrite DI, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Cellebrite DI 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Cellebrite DI 並不在名單上。</p>
</div><p>While Cellebrite DI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cellebrite DI 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Crescent Park Management L.P. 減少了其在 Cellebrite DI Ltd. $CLBT 的持倉